• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail

  • Print
  • Share
  • E-mail
Pediatric Labeling Date:  03/11/2003
Trade Name:  Temodar
Generic Name or Proper Name (*):  temozolomide
Indications Studied:  Recurrent CNS tumors
Label Changes Summary:  * Temozolomide effectiveness in children has not been demonstrated * New data from 2 open-label Phase 2 studies in pediatric patients 3-18 years of age. In one study there were 29 patients with recurrent brain stem glioma and 34 patients with recurrent high grade astrocyoma. In a second study there were 122 patients enrolled with various types of tumors; 113 CNS tumors and 9 non-CNS tumors. * The temozolomide toxicity profile in children is similar to adults
Product Labeling:  Labeling  Opens a new window
Sponsor:  Schering
Pediatric Exclusivity Granted Date:  11/20/2002
Therapeutic Category:  Antineoplastic